Ryan Bailey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ryan Bailey has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Albert To
Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii, Manoa, HI, USA
1 shared publication - Axel T. Lehrer
University of Hawaii at Manoa
1 shared publication - Brien K. Haun
Department of Tropical Medicine, Medical Microbiology, and Pharmacology, University of Hawaii Manoa, Honolulu, HI 96813, USA
1 shared publication - Cecilia M. Shikuma
Hawaii AIDS Clinical Research Program, John A. Burns School of Medicine, University of Hawaii-Manoa, Honolulu, Hawaii 96816, USA
1 shared publication - Gabriel Manninen
Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii, Honolulu, HI 96813, USA
1 shared publication - Helmut Kae
Science Department, Leeward Community College, University of Hawaii, Pearl City, HI 96782, USA
1 shared publication
Latest Publications
- Open Access
Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors
Background: A major goal for the vaccine field is the elicitation of broadly neutralizing antibodies (bnAbs) against pathogens that exhibit extensive antigenic diversity. Methods: In this study, we designed a rigid divalent immunogen for high avidity binding to the bnAb, VRC01, which targets the CD4 binding site (CD4bs) of the HIV spike protein. This was accomplished by covalently linking two HIV-1 gp120 antigens to a complementary antibody and crosslinking the light chains. Binding kinetics were analyzed using a novel gel shift assay and surface plasmon resonance. Results: The rigid divalent immunogen exhibits a higher affinity for VRC01-class antibodies compared to a flexible control, likely due to antigen pre-organization limiting the entropic penalty for divalent binding. Crucially, this immunogen exhibited divalent binding to VRC01 and monovalent binding to a non-CD4bs Ab, A32—a characteristic we refer to as “selective avidity.” Conclusions: In light of these results, we are preparing for in vivo vaccination experiments to test the immune focusing properties of this immunogen, the results of which may suggest broad application of the selective avidity concept.
Open AccessDivalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors
Background: A major goal for the vaccine field is the elicitation of broadly neutralizing antibodies (bnAbs) against pathogens that exhibit extensive antigenic diversity. Methods: In this study, we designed a rigid divalent immunogen for high avidity binding to the bnAb, VRC01, which targets the CD4 binding site (CD4bs) of the HIV spike protein. This was accomplished by covalently linking two HIV-1 gp120 antigens to a complementary antibody and crosslinking the light chains. Binding kinetics were analyzed using a novel gel shift assay and surface plasmon resonance. Results: The rigid divalent immunogen exhibits a higher affinity for VRC01-class antibodies compared to a flexible control, likely due to antigen pre-organization limiting the entropic penalty for divalent binding. Crucially, this immunogen exhibited divalent binding to VRC01 and monovalent binding to a non-CD4bs Ab, A32—a characteristic we refer to as “selective avidity.” Conclusions: In light of these results, we are preparing for in vivo vaccination experiments to test the immune focusing properties of this immunogen, the results of which may suggest broad application of the selective avidity concept.